Pregnancy
Anticoagulant Therapy in Pregnancy: Is It Safe?
LMWH (low-molecular-weight heparin) does not cross the placenta — the safest anticoagulant in pregnancy. Who needs it, how it is used and how delivery is planned.
8 min · 30 October 2025
Pregnant women with thrombophilia or a thrombosis history may need anticoagulant therapy. The most frequent question is safety: which medication does not harm the baby, and which must be avoided?
Which Drugs Are Safe?
- Low-molecular-weight heparin (LMWH — enoxaparin etc.): Does NOT cross the placenta; first choice in pregnancy. Decades of clinical experience show safety for mother and baby.
- Unfractionated heparin: Does not cross the placenta; preferred in special situations (renal failure, high-dose needs).
- Warfarin: Crosses the placenta and can cause fetal birth defects (especially weeks 6-12), fetal bleeding and CNS anomalies. Used only in very specific indications (mechanical valves) under specialist supervision.
- DOACs (rivaroxaban, apixaban etc.): Not recommended in pregnancy; they cross the placenta and safety data are insufficient. Considered safer in breastfeeding, but always a physician decision.
Who Should Receive LMWH?
- DVT/PE history before pregnancy.
- High-risk thrombophilia: homozygous FVL, combined mutations, antithrombin deficiency.
- Heterozygous carriers with family thrombosis history plus additional risk factors.
- Recurrent pregnancy loss + thrombophilia combination (evidence variable; physician decision).
- Pregnant women with mechanical heart valves (combined warfarin planning).
How Is It Administered?
LMWH is given by subcutaneous injections (usually once daily, into the abdomen). Mild bruising at the injection site is normal. Dose is adjusted by the physician based on weight and gestational week. Anti-Xa level measurement may be requested for dose monitoring in some cases.
Delivery Planning
- LMWH is not stopped during pregnancy; however a 24-hour interval before delivery is left (for regional anesthesia safety).
- In cesarean or high bleeding-risk situations, the physician sets the timing.
- Postpartum treatment continues up to 6 weeks; puerperium is riskier for thrombosis than pregnancy.
- LMWH does not pass into breast milk; it can be used safely while breastfeeding.
Additional Benefits and Limits
LMWH has shown potential to reduce some pregnancy complications (preeclampsia, pregnancy loss) beyond thrombosis prophylaxis; however this use is limited to the thrombophilia + recurrent loss combination and requires physician evaluation. Adding aspirin is an individual decision (standard especially for preeclampsia risk).
Conclusion
Anticoagulant therapy in pregnancy can be applied safely for mother and baby with the right drug choice (LMWH). Build your plan with your obstetrician, hematologist and genetic counseling team; regular follow-up makes completing your pregnancy safely possible.